Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 22, 2021, the board of directors (the "Board") of ImmunoGen, Inc.
(the "Company") elected Dr. Helen Thackray to the Board. The Board increased the
size of the Board from seven to eight members and elected Dr. Thackray to fill
the resulting vacancy. Dr. Thackray will also serve as a member of the
Governance and Nominating Committee of the Board.
Dr. Thackray will be compensated for her service as a director in accordance
with the Company's current non-employee director compensation policy. As a
non-employee director, Dr. Thackray will receive an annual fee of $40,000 for
being a member of the Board and an additional annual fee of $7,000 for being a
member of the Governance and Nominating Committee. Dr. Thackray will also
receive an initial grant of 30,000 deferred stock units ("DSUs") and an initial
stock option to purchase 44,000 shares of the Company's common stock. In
addition, beginning in 2022, Dr. Thackray will be entitled to an annual award of
15,000 DSUs and an annual stock option to purchase 44,000 shares of the
Company's common stock, prorated in 2022 based on the number of days between the
date of Dr. Thackray's election and the date of grant of the first annual DSU
and stock option award. The foregoing is a summary only and is qualified in its
entirety by reference to the Company's non-employee director compensation
policy, which was filed as Exhibit 10.2 to the Company's Current Report on Form
8-K, filed with the Securities and Exchange Commission on June 17, 2021, and is
incorporated herein by reference.
© Edgar Online, source Glimpses
IMMUNOGEN, INC. 
